Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
Clinical research conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) continues to ...
The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...
ByInvesting.com • 08 Sept 2024 Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial ...
In extensive-stage small cell lung cancer, a trial evaluating ifinatamab deruxtecan led to a dose-response benefit in response rate, from 8 mg/kg up to 12 mg/kg, for a 26% overall response rate (per ...
which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and ...
00:10 | From the World Congress on Lung Cancer, some exciting data were recently presented by Charles Rudin regarding an antibody drug conjugate [ADC], I believe is pronounced ifinatamab deruxtecan [I ...
The ADC oncology market is experiencing rapid growth, attracting over 200 pharmaceutical companies vying for leadership in this innovative therapeutic space. As competition intensifies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback